+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 2Years +
All Genders
ID06636383

Glycogen Storage Disease Type Ia Long-Term Monitoring Program Following DTX401 Treatment

Led by Ultragenyx Pharmaceutical Inc · Updated on 2026-10-14

140

Participants Needed

19

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to observe the long-term safety and effectiveness of DTX401 in people with Glycogen Storage Disease Type Ia GSDIa for at least 10 years after treatment. The study follows participants who previously received either a full or partial dose of DTX401, either in a clinical trial or after the drug was approved for use. Participants are monitored without receiving any new treatment as part of the study. They include two groups those treated with DTX401 in earlier clinical trials and those treated in post-marketing settings. The study collects information over a period of at least 10 years to track health outcomes and any side effects related to DTX401. During this time, participants undergo regular assessments including reports on serious adverse events, pregnancy outcomes, dietary intake, glucose levels, and clinical events related to GSDIa. Researchers also measure quality of life, hospital visits, and work or school attendance. The study involves ongoing data collection to understand the long-term effects and safety of DTX401, with participation lasting up to 10 years or more.

CONDITIONS

Brief Title

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

Research Team

P

Patients Contact: Trial Recruitment

H

HCPs Contact: Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here